To examine whether the MIR100HG/hnRNPA2B1/TCF7L2 axis plays a role in cetuximab resistance of CRC patients, we obtained paired tumor specimens from 12 individuals before the start of cetuximab treatment and at the time of tumor progression (Supplementary Table 1). Here, HNRNPA2B1 is linked to neoplasm.